Tempest Therapeutics TPST
NASDAQ TPST
$0.39 -0.01 (-2.17%)
As of: Nov 12, 2026 · 2:18 PM EST

Tempest Therapeutics (TPST) Net Income Attributable to Noncontrolling Interests (2018)

Updated

Tempest Therapeutics (TPST) reported Income from Non-Controlling Interests of $691,000 for Q4 2018.

Analysis

Tempest Therapeutics (TPST) Net Income Attributable to Noncontrolling Interests (2018) Analysis & Trends

For FY2018, Tempest Therapeutics posted Income from Non-Controlling Interests of $15,000.

  • By year, Income from Non-Controlling Interests came in at -$8,000 in FY2017.
  • Per Business Quant data, the three quarters before Q4 2018 came in at -$355,000 (Q3 2018), -$196,000 (Q2 2018) and -$125,000 (Q1 2018).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) NCI Net Income (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn -
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn -
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 2.00 Mn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 2.00 Mn
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn -1.00 Mn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn -
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 10.00 Mn
10 Tempest Therapeutics 5.91 Mn -11.91 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2018 691,000.00
Sep 30, 2018 -355,000.00
Jun 30, 2018 -196,000.00
Mar 31, 2018 -125,000.00
API Access

Tempest Therapeutics Net Income Attributable to Noncontrolling Interests API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=income-from-non-controlling-interests&ticker=TPST&period=max&api_key=YOUR_API_KEY